The expanded role of oncology pharmacists includes the opportunity to work in ambulatory settings, infusion centers, delivery of specialized in pharmacy services, evaluation of investigational new drugs, and manager roles in drug chain supply and in coordination of care.
Medicare Part D low-income subsidies alone are insufficient to improve the uptake and equitable use of high-cost, orally administered antimyeloma therapy.
Spending on novel therapies in high-risk bladder cancer had minimal impact on Oncology Care Model payments to practices, according to this cohort study and an average performance estimation.